Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
0(0%)
Results Posted
14%(1 trials)

Phase Distribution

Ph phase_2
1
14%
Ph phase_1
4
57%
Ph early_phase_1
2
29%

Phase Distribution

6

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
2(28.6%)
Phase 1Safety & dosage
4(57.1%)
Phase 2Efficacy & side effects
1(14.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(7)

Detailed Status

Completed7

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 12 (28.6%)
Phase 14 (57.1%)
Phase 21 (14.3%)

Trials by Status

completed7100%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_1

To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males

NCT05816356
completedphase_2

Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial

NCT02664181
completedearly_phase_1

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer

NCT02847000
completedearly_phase_1

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies

NCT02846935
completedphase_1

Cytochlor and Tetrahydrouridine as Radiosensitizers and Cisplatin Combined With Radiation Therapy in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity (Mouth) or Oropharynx (Throat)

NCT00077051
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT05816356Phase 1

To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males

Completed
NCT02664181Phase 2

Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial

Completed
NCT02847000Early Phase 1

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer

Completed
NCT02846935Early Phase 1

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies

Completed
NCT00077051Phase 1

Cytochlor and Tetrahydrouridine as Radiosensitizers and Cisplatin Combined With Radiation Therapy in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity (Mouth) or Oropharynx (Throat)

Completed
NCT01041443Phase 1

5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Completed
NCT00521183Phase 1

Cytochlor, Tetrahydrouridine, and External-Beam Radiation Therapy in Treating Patients With Cancer That Has Spread to the Brain

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7